Long-Term Effectiveness of Dupilumab in Moderate-to-Severe Atopic Dermatitis Across Different Body Regions in...

Real-world data on the long-term effectiveness of dupilumab in moderate-to-severe atopic dermatitis (AD) remains limited, particularly concerning regional disparities in improvement and the outcomes of extended dosing interval regimens. To evaluate the anatomical region-specific responses to dupilumab and the long-term effectiveness under extended dosing-interval regimens. This retrospective cohort study included moderate-to severe AD patients treated with dupilumab. Eczema Area and Severity Index (EASI)-75/90, Numerical Rating Scale (NRS) ≤ 1, and regional EASI reductions were assessed at 6/12/18 months. Patients reaching EASI-75 switched to extended dosing (every 3/4 weeks), with long-term effectiveness and influencing factors evaluated. 108 patients were included. Percentage reductions in EASI scores from baseline at 4, 6 and 12 months were as follows: head/neck: 58.52%, 82.36% and 89.36%; trunk: 77.95%, 85.82% and 94.68%; upper limbs: 77.11%, 86.49% and 95.45%; and lower limbs: 66.34%, 84.03% and 90.34%, respectively. EASI-75/90 and NRS ≤ 1 responses increased over 18 months, reaching 100%/96.97% and 96.97% respectively. No significant differences in effectiveness were observed between the every-three-weeks and every-four-weeks dosing groups. Dupilumab demonstrates sustained, region-specific effectiveness in moderate-to-severe AD, with delayed but progressive improvement in head and neck region(s). Patients achieving EASI-75 with stable disease can safely transition to every-three-weeks or every-four-weeks dosing regimens.